Silver Book Fact

Macugen to treat wet age-related macular degeneration (AMD)

A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.

Gragoudas E, Adamis A, Cunningham E, Feinsod M, et al. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805

Reference

Title
Pegaptanib for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2004
Authors
Gragoudas E, Adamis A, Cunningham E, Feinsod M, et al.
Volume & Issue
Volume 351, Issue 27
Pages
2805-16
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • After 9 years of tight blood pressure control, patients with type 2 diabetes had a 34% reduction in retinopathy progression and a 47% reduction in risk of visual acuity deterioration…  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy by 76% in type 1 diabetes patients who had not…  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.  
  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.